Lonza
生物製剤、低分子API、細胞および遺伝子治療薬の製造。
Lonza は、バーゼル事業で生物製剤、小分子 API、細胞および遺伝子治療薬の製造を行っています。同社は、上場主要市場全体でヘルスケア システム、研究所、OEM パートナー、または規制対象の輸出顧客に供給しています。
- Type
- manufacturer (our classification of the record, not a statement by the company)
- Role
- Manufacturer
- Location
- Basel, Switzerland
- Founded
- 1897
- Website
- lonza.com
- Categories
- 医療およびヘルスケア用品, 化学薬品とプラスチック
- Markets
- スイス, アメリカ合衆国, ドイツ, シンガポール
What is established and what is not
No facet of this company has been investigated yet. The facts below are collected records, not an assessment: nothing here confirms manufacturing, ownership or trading status beyond what each record literally says.
Verified facts
- certificate-page-on-site (amber), checked 2026-08-11 Company's own certification page
- domain-registered (green), checked 2026-08-02 Domain registry record
- web-presence-since (green), checked 2026-08-03 Internet Archive (Wayback)
- operating-permit (green), checked 2026-09-16 SHAB, Swiss Official Gazette of Commerce
- lei-active (green), checked 2026-07-21 GLEIF
- sanctions-clear (green), checked 2026-07-21 - screened by name only: no legal entity is established for this record, so this is not a clearance OpenSanctions
- registry-active-global (green), checked 2026-07-21 Zefix (Swiss commercial registry)
Claimed certifications, not confirmed by us
- Good Manufacturing Practice
- ISO 9001, Quality Management IAF CertSearch
Import rules for these goods
- Medical devices sold in the EU must carry CE marking under the Medical Device Regulation (EU) 2017/745, with a conformity assessment matched to the device risk class. European Commission (MDR)
- For the US market, the maker must have an FDA device establishment registration and product listing; most instruments also need 510(k) premarket clearance. US FDA (devices)